Clinicopathological Features and Prognosis of Pregnancy Associated Breast Cancer – A Matched Case Control Study

Madaras, Lilla; Kovács, Kristóf; Szász, Attila Marcell; Kenessey, István; Tőkés, Anna-Mária; Székely, Borbála; Baranyák, Zsuzsanna; Kiss, Orsolya; Dank, Magdolna; Kulka, Janina

doi:10.1007/s12253-013-9735-9

Cited by 51 publications

(67 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Luminal B breast cancer accounted for the largest proportion of all PABC patients, followed by triple-negative breast cancer. Consistent with our study, Soo reported that luminal B breast cancer (43.6%) and TNBC (35.9%) predominated in PABC [8]; while one study presented a different conclusion and showed that TNBC ranked first (48.4%) [9]. Some studies did not list the molecular types but reported the HR and HER-2 status and demonstrated that PABC was more prone to be HR-negative tumors, but no difference in the HER-2 status was reported compared with non-PABC as follows: HR negative (50.0% in PABC vs. 36.1% in non-PABC, P<0.001 (Yun et al)) [10], HR negative (32.6% in PABC vs. 15.9% in non-PABC, P=0.014 (Jessica et al)) [11], and HR negative (59.4% in PABC vs. 34.4% in non-PABC, P=0.03 (Michael et al)) [12]; only one study reported by Soo showed a higher HER-2 positive rate in PABC patients as follows: HER-2 positive (38.5% in PABC vs.…”

Section: Discussionsupporting

confidence: 89%

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Han

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pregnancy-associated breast cancer (PABC) is an aggressive disease, and sinceChinese authoritybegan to encourage childbearing in 2015, the incidence of PABC has increased. This study investigated the characteristics and survival of PABC patients. Methods: Patients with PABC who underwent surgery at Fudan University, Shanghai Cancer Center between 2005 and 2018 were enrolled.Data concerning the tumor characteristics, maternal state (whether first or non-first pregnancy ) and survival outcome were recorded. Pearson Chi-square tests were used to compare the characteristics of the tumors, and Kaplan-Meier methods were used to perform the survival analysis. Results: Overall, 203 PABC patients were recruited. Since 2015, 65.5% of non-first pregnant women were diagnosed with breast cancer, it’s 5.7 fold of the incidence of PABC in non-first pregnant women. No significant differences in tumor characteristics were observed between the patients who were in their first pregnancy and those in non-first pregnancy. Among the entire PABC population, luminal B breast cancer accounted for the largest proportion (38.4%), followed by triple-negative breast cancer (TNBC, 30.0%). The distribution of the molecular subtypes of PABC and non-PABC differed (P<0.001) as follows: in the PABC patients, Luminal B 38.4%, Triple negative breast cancer (TNBC) 30.1%, Human Epidermal Growth Factor Receptor 2 (HER-2) overexpression 15.8%, and Luminal A 10.8%; in the non-PABC patients, Luminal A 50.9%, Luminal B 20.1%, TNBC 17.4%, and HER-2 overexpression 8.0%. The 3-year disease free survival (DFS) of all PABC patients was 80.3%. The 3-year DFS of the patients in the first-pregnancy group was 78.4%, and that of the patients in the non-first-pregnancy group was 83.7% (P=0.325). Conclusions: Our study proved that the proportion of women who developed PABC during the second or third pregnancy was extremely high relative to the newborn populations. The patients in the PABC population tended to present more luminal B and TNBC breast cancer than the non-PABC patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Han

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The increased concentration of gestational hormones with growth promoting effects (i.e., estrogen, insulin-like growth factor 1, and progesterone) might result in a more aggressive breast cancer biology [9]. Although some studies did not reveal any major different expression of breast cancer biomarkers (e.g., hormone receptors and HER2) compared with non-pregnant age-matched breast cancer patients [10][11][12], other studies showed that BCP is more commonly associated with unfavorable tumor biology reflected by the predominance of triple-negative breast cancers [13][14][15]. Recently, a series of experiments showed that BCP is associated with specific activated signaling pathways, high expression of potentially relevant cancer targets like SRC, Wnt/b-catenin, RANKL [16,17], and, in addition, low expression of tumor infiltrating lymphocytes [18].…”

Section: Introductionmentioning

confidence: 99%

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

Lambertini

Kamal

Peccatori

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The rule of thumb of chemotherapy - avoiding first trimester exposure and starting therapy in the second trimester - can be considered applicable for classic agents that are used in managing pregnant breast cancer patients. Anthracycline-based regimens are considered the standard of care in managing BCP. Recently, a growing amount of data suggests the safety of taxanes during pregnancy. Pregnancy in cancer patients should be considered as "high risk": once the systemic treatment is initiated, regular fetal monitoring is highly recommended. Emerging data are available on the relative long-term safety secondary to anthracycline exposure during pregnancy. A continued monitoring of the health of individuals with prenatal exposure to chemotherapy into adulthood is recommended for the possible occurrence of long-term side effects.

show abstract

“…The survival rates of the PABC patients compared to those of the non-PABC patients were conflicting. Most studies [8,9,15,10,14,[16][17][18][19][20][21][22]] demonstrated a worse prognosis in PABC after excluding prognostic factors, including age, the tumor size, and lymph node status, while eight studies [23][24][25][26][27][28][29][30] showed no difference in survival between PABC and non-PABC patients after correcting for these factors.…”

Section: Discussionmentioning

confidence: 99%

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Han

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: Pregnancy-associated breast cancer (PABC) is an aggressive disease, and sinceChinese authoritybegan to encourage childbearing in 2015, the incidence of PABC has increased. This study investigated the characteristics and survival of PABC patients. Methods: Patients with PABC who underwent surgery at Fudan University, Shanghai Cancer Center between 2005 and 2018 were enrolled.Data concerning the tumor characteristics, maternal state (whether first or non-first pregnancy ) and survival outcome were recorded. Pearson Chi-square tests were used to compare the characteristics of the tumors, and Kaplan-Meier methods were used to perform the survival analysis. Results: Overall, 203 PABC patients were recruited. Since 2015, 65.5% of non-first pregnant women were diagnosed with breast cancer, it’s 5.7 fold of the incidence of PABC in non-first pregnant women. No significant differences in tumor characteristics were observed between the patients who were in their first pregnancy and those in non-first pregnancy. Among the entire PABC population, luminal B breast cancer accounted for the largest proportion (38.4%), followed by triple-negative breast cancer (TNBC, 30.0%). The distribution of the molecular subtypes of PABC and non-PABC differed (P<0.001) as follows: in the PABC patients, Luminal B 38.4%, Triple negative breast cancer (TNBC) 30.1%, Human Epidermal Growth Factor Receptor 2 (HER-2) overexpression 15.8%, and Luminal A 10.8%; in the non-PABC patients, Luminal A 50.9%, Luminal B 20.1%, TNBC 17.4%, and HER-2 overexpression 8.0%. The 3-year disease free survival (DFS) of all PABC patients was 80.3%. The 3-year DFS of the patients in the first-pregnancy group was 78.4%, and that of the patients in the non-first-pregnancy group was 83.7% (P=0.325). Conclusions: Our study proved that the proportion of women who developed PABC during the second or third pregnancy was extremely high relative to the newborn populations. The patients in the PABC population tended to present more luminal B and TNBC breast cancer than the non-PABC patients.

show abstract

Clinicopathological Features and Prognosis of Pregnancy Associated Breast Cancer – A Matched Case Control Study

Cited by 51 publications

References 37 publications

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Exploring the safety of chemotherapy for treating breast cancer during pregnancy

Clinical Features and Survival of Pregnancy-Associated Breast Cancer: A Retrospective Study of 203 Cases in China

Contact Info

Product

Resources

About